ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported positive interim results for their core drug IMM01, showing significant efficacy in treating various blood cancers. The drug, in combination with other treatments, has demonstrated increasing response rates in clinical trials, with promising outcomes presented at the 2024 ASCO Annual Meeting. The company’s advancements highlight a strong development trajectory of their drug pipeline since their listing on the Stock Exchange in September 2023.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
